An open-label, single-arm study to describe glucocorticoid use in rheumatoid arthritis patients treated with Tocilizumab in daily clinical practice and to evaluate systematic glucocorticoid dose reduction once low disease activity is reached (ACT-ALONE).

Trial Profile

An open-label, single-arm study to describe glucocorticoid use in rheumatoid arthritis patients treated with Tocilizumab in daily clinical practice and to evaluate systematic glucocorticoid dose reduction once low disease activity is reached (ACT-ALONE).

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jan 2015

At a glance

  • Drugs Tocilizumab (Primary) ; Methylprednisolone
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ACT-ALONE
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Apr 2013 Planned End Date changed from 1 Apr 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top